- Conditions
- Bipolar I Depression
- Interventions
- Armodafinil, Placebo
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Escondido, California • Lafayette, California + 35 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 7,623
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Elobixibat 10 mg/day, Elobixibat 5 mg/day, Placebo
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 41 more
- Conditions
- Prostate Cancer
- Interventions
- IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE, Proton (prostate bed) to 70.2 CGE, IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE, Proton to 66.6 CGE
- Radiation
- Lead sponsor
- Proton Collaborative Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2050
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Jacksonville, Florida • Warrenville, Illinois + 3 more
- Conditions
- Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
- Interventions
- VERVE-102
- Drug
- Lead sponsor
- Verve Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 10
- States / cities
- Dothan, Alabama • Pomona, California • Boca Raton, Florida + 7 more
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- AZD2693, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 36
- States / cities
- Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 32 more
- Conditions
- Leukemia
- Interventions
- cytarabine, idarubicin, pravastatin sodium
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 185
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 123 more
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Electronic Health Record Review
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- ABC/DTG/3TC FDC, Ongoing cART regimen
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 87
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 64 more
- Conditions
- Epilepsy
- Interventions
- RNS® System implantation, RNS® System responsive stimulation
- Procedure · Device
- Lead sponsor
- NeuroPace
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 8 more
- Conditions
- Primary or Secondary Hypogonadism, Constitutional Delay in Growth and Puberty (CDGP)
- Interventions
- Testosterone Gel (1%)
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 13 Years to 17 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Torrance, California • Jacksonville, Florida + 6 more
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
- Interventions
- Pembrolizumab, Sonidegib
- Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Cancer, Tumor
- Interventions
- No intervention
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Breast Cancer
- Interventions
- exemestane, Placebo
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,598 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2011
- U.S. locations
- 150
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 129 more
- Conditions
- Progressive Supranuclear Palsy (PSP)
- Interventions
- ABBV-8E12, Placebo solution for IV infusion on Day 15
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 19 more
- Conditions
- Ischemic Stroke, Intracranial Hematoma
- Interventions
- Mechanical thrombectomy, Minimally invasive surgery
- Device · Other
- Lead sponsor
- Penumbra Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 27
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Newark, Delaware + 24 more
- Conditions
- Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma
- Interventions
- Atezolizumab, Bevacizumab, Computed Tomography, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 907
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 574 more
- Conditions
- Idiopathic Membranous Nephropathy
- Interventions
- Rituximab, Cyclosporine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 13 more
- Conditions
- NASH/MASH, NAFLD/MASLD
- Interventions
- Efruxifermin, Placebo
- Drug
- Lead sponsor
- Akero Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 139
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 117 more
- Conditions
- Chronic Myocardial Ischemia, Refractory Angina Pectoris, Advanced Coronary Heart Disease
- Interventions
- Auto-CD34+ cells, Placebo: Diluent used to suspend Auto-CD34+ cells, Standard of care
- Biological · Other
- Lead sponsor
- Lisata Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 38 more
- Conditions
- Hypertension, Hypercortisolemia, Cushing Syndrome
- Interventions
- Osilodrostat, Placebo
- Drug
- Lead sponsor
- RECORDATI GROUP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Canton, Ohio • Weslaco, Texas
- Conditions
- Myopia
- Interventions
- MiSight 1 Day
- Device
- Lead sponsor
- CooperVision, Inc.
- Industry
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 2,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2030
- U.S. locations
- 47
- States / cities
- Gilbert, Arizona • Centerton, Arkansas • Berkeley, California + 42 more
- Conditions
- Hip Osteoarthritis, Avascular Necrosis of Hip
- Interventions
- Intraoperative Fluoroscopic Computer Navigation
- Procedure
- Lead sponsor
- Southeast Orthopedic Specialists
- Network
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Extensive-Stage Small Cell Lung Cancer
- Interventions
- Carboplatin, Palifosfamide-tris, Etoposide
- Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Los Angeles, California • Santa Rosa, California + 36 more
- Conditions
- Critical Illness, Depressive Symptoms
- Interventions
- Ketamine (0.5 mg/kg), Normal Saline (0.9% NaCl)
- Drug · Other
- Lead sponsor
- Hospital Italiano de Buenos Aires
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida